Canaccord Genuity reissued their buy rating on shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) in a research report report published on Friday, May 12th. They currently have a $7.00 price target on the biotechnology company’s stock.
“CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18.”,” Canaccord Genuity’s analyst commented.
Aptose Biosciences (NASDAQ APTO) traded up 0.84% during trading on Friday, reaching $1.20. The company’s stock had a trading volume of 291,672 shares. The firm’s market cap is $26.10 million. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $3.20. The stock’s 50 day moving average is $1.11 and its 200-day moving average is $1.11.
COPYRIGHT VIOLATION NOTICE: “Aptose Biosciences’ (APTO) “Buy” Rating Reiterated at Canaccord Genuity” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/06/17/aptose-biosciences-inc-apto-rating-reiterated-by-canaccord-genuity-updated-updated-updated.html.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Baker BROS. Advisors LP acquired a new stake in shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 404,211 shares of the biotechnology company’s stock, valued at approximately $909,000. Baker BROS. Advisors LP owned 3.14% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 11.19% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
What are top analysts saying about Aptose Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aptose Biosciences Inc. and related companies.